Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems
Dino Luethi, Karolina E. Kolaczynska, Melanie Walter, Masaki Suzuki, Kenner C Rice, Bruce E. Blough, Marius C. Hoener, Michael H. Baumann, Matthias E. Liechti
Journal of Psychopharmacology April 30, 2019 DOI: 10.1177/0269881119844185 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | In vitro study Peer reviewed |
|---|---|
| Population | Human embryonic kidney 293 cells transfected with human monoamine transporters |
| Topics | MDMA Serotonin |
| Keywords | Monoaminergic Pharmacology Methamphetamine Monoamine neurotransmitter Dopamine Methylenedioxy |
| Citations | 39 |
| Key points | N-demethylated metabolites of MDMA and methylone circulate in unconjugated form and could contribute to the in vivo activity of the parent compounds in human users. |
Abstract
Background: Amphetamine analogs with a 3,4-methylenedioxy ring-substitution are among the most popular illicit drugs of abuse, exerting stimulant and entactogenic effects. Enzymatic N-demethylation or opening of the 3,4-methylenedioxy ring via O-demethylenation gives rise to metabolites that may be pharmacologically active. Indeed, previous studies in rats show that specific metabolites of 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxymethcathinone (methylone) and 3,4-methylenedioxypyrovalerone (MDPV) can interact with monoaminergic systems.
Aim: Interactions of metabolites of MDMA, methylone and MDPV with human monoaminergic systems were assessed.
Methods: The ability of parent drugs and their metabolites to inhibit uptake of tritiated norepinephrine, dopamine and serotonin (5-HT) was assessed in human embryonic kidney 293 cells transfected with human monoamine transporters. Binding affinities and functional activity at monoamine transporters and various receptor subtypes were also determined.
Results: MDMA and methylone displayed greater potency to inhibit norepinephrine uptake as compared to their effects on dopamine and 5-HT uptake. N-demethylation of MDMA failed to alter uptake inhibition profiles, whereas N-demethylation of methylone decreased overall transporter inhibition potencies. O-demethylenation of MDMA, methylone and MDPV resulted in catechol metabolites that maintained norepinephrine and dopamine uptake inhibition potencies, but markedly reduced activity at 5-HT uptake. O-methylation of the catechol metabolites significantly decreased norepinephrine uptake inhibition, resulting in metabolites lacking significant stimulant properties.
Conclusions: Several metabolites of MDMA, methylone and MDPV interact with human transporters and receptors at pharmacologically relevant concentrations. In particular, N-demethylated metabolites of MDMA and methylone circulate in unconjugated form and could contribute to the in vivo activity of the parent compounds in human users.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 23
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- The risk of chronic psychedelic and MDMA microdosing for valvular heart disease Journal of Psychopharmacology August 12, 2023
- The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative International Journal of Molecular Sciences July 31, 2021
- Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents Expert Opinion on Drug Safety August 15, 2023
- Pharmacological effects of methylone and MDMA in humans Frontiers in Pharmacology February 17, 2023
and 18 more in the library
Cites 23
- Human Pharmacology of MDMA Therapeutic Drug Monitoring March 19, 2004
- Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling Swiss Medical Weekly January 11, 2015
- Pharmacological profile of novel psychoactive benzofurans British Journal of Pharmacology March 13, 2015
- MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Frontiers in Genetics 2012
- Pharmacokinetic, Ambulatory, and Hyperthermic Effects of 3,4-Methylenedioxy-N-Methylcathinone (Methylone) in Rats Frontiers in Psychiatry November 17, 2017
and 18 more in the library